Clinical Trial Update: BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BMN 673 (talazoparib), an oral PARP inhibitor, in ovarian cancer patients with deleterious BRCA1/2 mutations who previously received PA…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• BMN 673 (talazoparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-05-24